Trial Profile
A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Ibritumomab tiuxetan; Rituximab
- Indications Anaplastic large cell lymphoma; B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Jul 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2020.
- 13 Apr 2016 Status changed from recruiting to active, no longer recruiting.